Free Trial
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$32.48
$32.48
50-Day Range
$32.18
$32.48
52-Week Range
$7.26
$32.50
Volume
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.65

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
11.8% Downside
$28.65 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($1.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.44 out of 5 stars

Medical Sector

882nd out of 923 stocks

Pharmaceutical Preparations Industry

408th out of 423 stocks

CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CBAY Stock News Headlines

Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
CBAY Oct 2024 33.000 call
CBAY Oct 2024 29.000 put
Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY
CBAY Jan 2026 37.000 call
CBAY Feb 2024 33.000 call
CBAY Jan 2025 8.000 put
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
5/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBAY
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.65
High Stock Price Target
$32.50
Low Stock Price Target
$15.00
Potential Upside/Downside
-11.8%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
12 Analysts

Profitability

Net Income
$-105,370,000.00
Pretax Margin
-339.11%

Debt

Sales & Book Value

Annual Sales
$31.07 million
Book Value
$2.58 per share

Miscellaneous

Free Float
106,693,000
Market Cap
$3.73 billion
Optionable
Optionable
Beta
0.32
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives


CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

12 brokerages have issued twelve-month target prices for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they anticipate the company's stock price to reach $28.65 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analyst estimates of $0.42 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT).AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Walleye Trading LLC (0.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Janet Dorling, Kurt Von Emster, Paul T Quinlan and Sujal Shah.
View institutional ownership trends
.

This page (NASDAQ:CBAY) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners